Park Medi World Limited delivered robust financial results for the quarter ended June 30, 2026, reporting a 35% year-on-year surge in net profit to ₹89 crore, driven by strong patient volume growth and improved operational efficiency. Revenue from operations rose 19% to ₹476 crore, while EBITDA expanded 20% to ₹126 crore. The hospital group also unveiled an aggressive expansion roadmap, targeting a bed capacity of 5,740 by March 2028, largely funded through internal accruals and IPO proceeds without fresh debt.

The filing was submitted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with Abhishek Kapoor, Company Secretary & Compliance Officer, certifying the disclosure to BSE Limited and the National Stock Exchange of India Limited. The earnings conference call, held on August 04, 2026, featured Managing Director Dr. Ankit Gupta, Whole-Time Director & CEO Dr. Sanjay Sharma, Group CFO Mr. Rajesh Sharma, and Chief Strategy Officer Mr. Sudesh Sharma.

Financial Performance

*Figures for Q1FY26 derived from disclosed growth percentages.

Group CFO Rajesh Sharma attributed the margin expansion to reduced interest outgo following substantial term debt repayment. As of June 30, 2026, term debt excluding lease liability stood at ₹25.6 crore, down from ₹28.2 crore in March 2026. The company maintained a fixed deposit of ₹300 crore and net worth of ₹2,100 crore.

Operational Metrics and Case Mix

Operational volumes showed consistent growth, with In-Patient Department (IPD) volumes rising 16% to 26,304 patients and Out-Patient Department (OPD) volumes increasing 17% to 2,23,446 patients. Average Revenue Per Occupied Bed (ARPOB) grew 12% to ₹30,444, while Average Length of Stay (ALOS) improved by 8% to 5.9 days.

The case mix shifted towards high-end tertiary and quaternary care, contributing approximately 62% of total revenue, an increase of 440 basis points year-on-year. Key specialties included neurology (14.5%), cardiology (12%), urology (11%), oncology (9-10%), joint replacement (9.5%), and gastroenterology (7%). Network occupancy moderated to 56% from 68% in Q1FY26, reflecting the immediate inclusion of 960 new beds in Bhatinda, Agra, and Panchkula in the denominator during their ramp-up phase.

Expansion Roadmap

Park Medi World commissioned The Medicity Hospital in Rudrapur, Uttarakhand, on August 2, 2026, marking its entry into its sixth state. The 330-bed NABH-accredited facility was acquired for ₹177 crore. Additionally, the company announced a definitive agreement to acquire Mehar Hospital in Zirakpur, Punjab, a 150-bed facility valued at ₹107 crore. A 100-bed extension at Palam Vihar, Gurgaon, named 'Park Platinum', will bring consolidated Gurgaon capacity to 750 beds.

Total bed capacity stood at 3,960 as of June 30, 2026, up 32% year-on-year. The company expects to add 1,490 beds in calendar year 2026, reaching 4,740 beds by end-FY27. By March 2028, capacity is projected to reach 5,740 beds. Blended CAPEX per bed is expected to remain at ₹36 lakh over FY27 and FY28, supported by ₹767 crore in planned capital expenditure for 2,130 new beds.

What the Numbers Show

The divergence between revenue growth (19%) and PAT growth (35%) highlights the leverage effect of debt reduction on bottom-line profitability. With term debt significantly lowered, interest savings are flowing directly to net profit, enhancing return on capital employed. Furthermore, the shift in payer mix towards a targeted 70:30 split (government schemes to private/self-pay) over the next 12-18 months aims to stabilize ARPOB growth within a 10-12% annual band, mitigating reliance on lower-margin government reimbursements while maintaining affordability.

Management guided full-year FY27 revenue at ₹2,080 crore, EBITDA at ₹530 crore, and PAT at ₹360 crore, implying growth rates of 24%, 25%, and 32% respectively over FY26. The CGHS rate revision, implemented in October 2025, is expected to provide a 7-7.5% benefit, though management noted that additional revenues will be reinvested into CAPEX and equipment upgrades rather than directly boosting margins.

Park Medi World Limited ( park medi world ) will participate in three investor conferences in Mumbai during August 2026, providing analysts and institutional investors with opportunities for direct engagement with management. The company disclosed the schedule under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, confirming that no unpublished price-sensitive information will be shared during these meetings.

The engagements are scheduled for August 12, 13, and 25, 2026. All three events will be conducted in a physical mode, allowing for both group discussions and one-on-one meetings. The conferences are organized by Emkay Global Financial Services, Equirus, and Antique Healthcare, respectively, and will take place at prominent venues in Mumbai’s business districts.

Conference Schedule

The detailed schedule for the investor interactions is as follows:

All meetings are set to begin at 10:00 a.m. local time. The company noted that the schedule is subject to change due to exigencies on the part of either the investors or the company.

Compliance and Disclosure

Abhishek Kapoor, Company Secretary & Compliance Officer of Park Medi World Limited, issued the disclosure on August 05, 2026. The announcement was submitted to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE), where the company trades under the symbol PARKHOSPS.

The disclosure emphasizes strict adherence to insider trading regulations by pre-committing that the representatives will not discuss any unpublished price-sensitive information. This standard practice ensures market integrity while allowing management to address general operational queries and strategic outlooks within public domain knowledge. The full disclosure is also available on the company’s official website.